Compare VTVT & ATLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTVT | ATLX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7M | 124.5M |
| IPO Year | 2015 | 2012 |
| Metric | VTVT | ATLX |
|---|---|---|
| Price | $33.27 | $3.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $53.00 | $12.00 |
| AVG Volume (30 Days) | 53.6K | ★ 413.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $92,491.00 |
| Revenue This Year | N/A | $64,564.67 |
| Revenue Next Year | N/A | $785.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.00 | $3.24 |
| 52 Week High | $44.00 | $8.25 |
| Indicator | VTVT | ATLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 31.75 |
| Support Level | $30.14 | N/A |
| Resistance Level | $33.76 | $3.92 |
| Average True Range (ATR) | 2.64 | 0.21 |
| MACD | -0.33 | -0.02 |
| Stochastic Oscillator | 19.76 | 2.31 |
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.